Studies show a potential negative interaction between Descovy and Prezcobix, and thus it may be risky taking these drugs concomitantly. Below is info on both meds, their active ingredients as well as their interaction.
Descovy is a medicine approved for the treatment of HIV (human immunodeficiency virus). It is a combination of two other antiretroviral drugs proven effective in decelerating the progression of HIV: tenofovir alafenamide (25 mg) (possesses a lower risk of bone- and kidney-related negative after-effects than the older versions of tenofovir) and emtricitabine (200 mg) . These pills are made by Gilead Sciences.
Prezcobix is a combination drug with an approval from the FDA (Food and Drug Administration) for treating HIV. It contains two active ingredients: 150 mg of cobicistat and 800 mg of darunavir. Correct and continuous intake of this med with strict adherence can help achieve undetectable viral load as well as prevent the risk of HIV transmission . It is produced by Janssen.
Research carried out on the coadministration of tenofovir alafenamide/emtricitabine with cobicistat/darunavir shows that there is a possible increase in concentrations of the two meds in plasma , which can lead to the increased severity of side effects. It is not advised to mix them together. On occasion, when the concomitant usage is prescribed by a healthcare professional, users require close monitoring of their condition. It is important to inform a doctor of other medicines, supplements, and herbal treatments being taken as well as report any unusual body changes or side effects.